Plasma N-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.

Juliane MenzelTamara ŠtambukOlga KuxhausNajda RudmanFrano VučkovićJerko ŠtambukCatarina SchibornDario RahelićStefan DietrichOlga GornikMarkus PerolaHeiner BoeingMatthias Bernd SchulzeGordan Lauc

Published in: Diabetes care (2020)

Selected N-glycans improve type 2 diabetes and CVD prediction beyond established risk markers. Plasma protein N-glycan profiling may thus be useful for risk stratification in the context of precisely targeted primary prevention of cardiometabolic diseases.

Keyphrases

type diabetes
cell surface
insulin resistance
cancer therapy
skeletal muscle
adipose tissue
amino acid